Related Experiment Video
Updated: Mar 13, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Effect of SGLT2 Inhibitors on Atrial Electromechanical Delay in Patients with Type 2 Diabetes
Muhammed Erzurum1, Mehmet Ali Felekoğlu2, Nadire Isık Erol Algül3
1Department of Cardiology, Karabük Training and Research Hospital, Turkey.
Abstract:
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been associated with lower atrial fibrillation (AF) incidence in diabetes mellitus (DM). Atrial electromechanical delay (AEMD) is an electrophysiological marker related to AF development. This study evaluated AEMD changes in type 2 DM patients treated with an SGLT2 inhibitor (dapagliflozin or empagliflozin). Baseline and 4-month follow-up data of 50 patients with type 2 diabetes who initiated SGLT2 inhibitor therapy were retrospectively obtained from medical records and analyzed. AEMD was measured using echocardiography and tissue Doppler. Inter-AEMD and intra-AEMD intervals were calculated. Left atrial volume (LAVOL) significantly decreased (45.23 ± 9.27 vs 42.21 ± 9.16; P < .001), while left intra-AEMD (19.58 ± 7.53 vs 16.76 ± 7.53; P <.001), right intra-AEMD (14.42 ± 5.81 vs 12.46 ± 8.05; P = .016), and inter-AEMD (34 ± 9.41 vs 29.22 ± 9.44; P < .001) were significantly reduced. Inter-AEMD change correlated with LAVOL, E/E' ratio, body mass index, and mean blood pressure changes (all P <.05). In diabetic patients treated with SGLT2 inhibitors, AEMD reduction was observed after 4 months, with favorable metabolic and hemodynamic effects. These findings suggest that SGLT2 inhibitors may protect against AF by improving atrial electromechanical function.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Diabetes Mellitus: Type 2 and Gestational
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Oral Hypoglycemic Agents: Biguanides and Glitazones

